Thermo Fisher Scientific Inc. (TMO) - Stock Analysis

Last updated: Sep 6, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth.

Loading chart data...

Idea window: 11/17/2025 – 11/24/2025Sector: Healthcare

AI Analyst Overview

Last Price
$609.82
Market Cap
$226.62B
1D Return
+1.10%
YTD Return
+5.45%

Loading chart data...

Valuation Metrics

P/E
32.8
P/B
4.3
P/S
4.9
EV/EBITDA
24.6
Div Yield
0.30%

Fundamental Analysis

7.0

Key Financial Insights: • Strong cash generation • Rising leverage • Weaker liquidity Thermo Fisher remains highly profitable and cash-generative, but rising leverage, weaker liquidity, intangible-asset concentration, and richer valuation warrant caution.

CashFlow
Leverage

Price Behavior

6.0

Key Price Behavior Insights: • Recent rebound • Support holding • Resistance overhead Support Level: $600–$611 Resistance Level: $618–$622 TMO is mildly bullish over the last month, holding above $611 support with upside toward $618–$622, but a break below $600 would weaken the setup.

Bullish
Technical

Sentiment & News

7.0

Key News Insights: • Biopharma Recovery • Acquisition Expansion • Valuation Concern Thermo Fisher's growth, acquisitions, innovation, and institutional demand support momentum, but elevated valuation and macro risks warrant caution.

ThermoFisher
ValuationRisk
AI

AI Summary

7.0
Positive

TMO's recovery is operationally real, but at ~30x earnings and ~21x EBITDA, upside now depends on accelerated organic growth and acquisition returns; investors should wait for evidence of sustained Pharma/Biotech momentum and disciplined deleveraging before adding aggressively.

BiopharmaRecovery
ValuationRisk
CapitalAllocation
AI summary updated 5 days ago

Description

Thermo Fisher Scientific is a global provider of instruments, reagents, consumables and services for life sciences research, clinical diagnostics, and biopharmaceutical production across North America, Europe, Asia-Pacific and other markets. The company operates through four reporting segments—life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services—selling to pharmaceutical, biotechnology, clinical, academic, government and industrial customers via direct sales, e-commerce and distributors. Founded in 1956, Thermo Fisher is headquartered in Waltham, Massachusetts.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 17Nov 24TMOThermo Fisher Scientific Inc.
Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth.
Closed+3.3%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.